Full Publications

 

2018

Rulle U, Tsourti Z, Casanova R, Deml KF, Verbeken E, Thunnissen E, Warth A, Cheney R, Sejda A, Speel EJ, Bille Madsen L, Nonaka D, Navarro A, Sansano I, Marchetti A, Finn SP, Monkhorst K, Kerr KM, Haberecker M, Wu C, Zygoura P, Kammler R, Geiger T, Gendreau S, Schulze K, Vrugt B, Wild P, Moch H, Weder W, Tuna Ciftlik A, Dafni U, Peters S, Bubendorf L, Stahel RA, Soltermann A. Computer-based intensity measurement assists pathologists in scoring PTEN immunohistochemistry-Clinical associations in NSCLC patients of the ETOP Lungscape cohort. Journal of Thoracic Oncology 2018, in press.

(ETOP Lungscape) (Journal impact factor 10.336)

 

 

2017

Letovanec I, Finn S, Zygoura P, Smyth P, Soltermann A, Bubendorf L, Speel EJ, Marchetti A, Nonaka D, Monkhorst K, Hager H, Martorell M, Sejda A, Cheney R, Hernandez-Losa J, Verbeken E, Weder W, Savic S, Di Lorito A, Navarro A, Felip E, Warth A, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dienemann H, Dziadziuszko R, Vansteenkiste J, O'Brien C, Geiger T, Sherlock J, Schageman J, Dafni U, Kammler R, Kerr KM, Thunnissen E, Stahel R, Peters S; ETOP Lungscape Consortium. Evaluation of NGS and RT-PCR methods for ALK rearrangement in European NSCLC patients: Results from the ETOP Lungscape Project. Journal of Thoracic Oncology 2017; 13 (3): 413-425.

(ETOP Lungscape) (Journal impact factor 10.336)

 

Kerr KM, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, Finn S, Biernat W, Vliegen L, Losa JH, Marchetti A, Cheney R, Warth A, Speel EJ, Blackhall F, Monkhorst K, Jantus Lewintre E, Tischler V, Clark C, Bertran-Alamillo J, Meldgaard P, Gately K, Wrona A, Vandenberghe P, Felip E, De Luca G, Savic S, Muley T, Smit EF, Dingemans AC, Priest L, Baas P, Camps C, Weder W, Polydoropoulou V, Geiger TR, Kammler R, Sumiyoshi T, Molina MA, Shames DS, Stahel RA, Peters S; ETOP Lungscape Consortium. Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project. Annals of Oncology. 2018; 29 (1): 200-208.

(ETOP Lungscape) (Journal impact factor 13.926)

 

Bubendorf L, Dafni U, Schöbel M, Finn SP, Tischler V, Sejda A, Marchetti A, Thunnissen E,. Verbeken EK, Warth A, Sansano I, Cheney T, Speel EJM, Daisuke Nonaka D, Monkhorst K, Hager H, Martorell M, Savic S, Kerr KM, Tan Q, Tsourti Z, Geiger TR, Kammler R, Schulze K, Das-Gupta A, Shames D, Peters S, Stahel RA; Lungscape Consortium. Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project. Lung Cancer 2017; 111: 143-149.

(ETOP Lungscape) (Journal impact factor 4.486)

 

Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Ponce Aix, S, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps, C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan, E. Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames DS, Molina-Vila MA, Stahel RA; BELIEF collaborative group. Phase II trial of erlotinib and bevacizumab in patients with advanced non-small cell lung cancer and activating EGFR mutations (BELIEF). Lancet Respiratory Medicine 2017; 5 (5): 435-444.

(ETOP BELIEF) (Journal impact factor 21.466)

 

Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AMJ, Juan Vidal O, Palmero Sanchez R, Villa Guzmánu JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJM, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF; EMPHASIS-lung collaborative group. Randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer failing first line platinum-based doublet chemotherapy stratified by Veristrat good versus Veristrat poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung trial. Journal of Thoracic Oncology 2017; 12 (4): 752-762.

(ETOP EMPHASIS-lung) (Journal impact factor 10.336)

 

 

 

2014

Peters S, Weder W, Dafni U, Kerr KM, Bubendorf L, Meldgaard P, O'Byrne KJ, Wrona A, Vansteenkiste J, Felip E, Marchetti A, Savic S, Lu S, Smit E, Dingemans AMC, Blackhall FH, Baas P, Camps C, Rosell R, and Stahel RA; ETOP Lungscape Investigators. Lungscape: resected non-small cell lung cancer outcome by clinical and pathological parameters. Journal of Thoracic Oncology 2014; 9 (11): 1675-1684.

(ETOP Lungscape) (Journal impact factor 10.336)

 

Blackhall FH, Peters S, Bubendorf L, Dafni U, Kerr KM, Hager H, Soltermann A, O’Byrne KJ, Dooms C, Sejda A, Hernández-Losa J, Marchetti A, Savic S, Tan Q, Thunnissen E, Speel EJM, Cheney R, Nonaka D, de Jong J, Martorell M, Letovanec I, Rosell R, and Stahel RA. Prevalence and Clinical Outcomes for Patients with ALK-Positive Resected Stage I to III Adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape Project. Journal of Clinical Oncology 2014; 32 (25): 2780-2787.

(ETOP Lungscape) (Journal impact factor 26.303)

 

Patton S, Normanno N, Blackhall FH, Murray S, Kerr KM, Dietel M, Filipits M, Benlloch S, Popat S, Stahel RA, and Thunnissen E. Assessing standardization of molecular testing for non-small cell lung cancer: Results of a worldwide External Quality Assessment (EQA) scheme for EGFR mutation testing. British Journal of Cancer 2014; 111 (2): 413-420.

(ETOP Lungscape) (Journal impact factor 5.922)

 

 

 

2011

Gridelli C, Stahel RA, Besse B, Ciardiello F, Felip E, Gasparini S, Graziano P, Rossi A, and de Marinis F. Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting. Lung Cancer 2011; 74: 544-548.

(ETOP general) (Journal impact factor 4.486)

 

 

2010

Stahel RA, Baas P, Faivre-Finn C, Dooms C, Passlick B, Mazières J, Cappuzzo F, Früh M, Sorensen JB, Blackhall FH, Taron M, Gridelli C, O'Byrne KJ, and Rosell R. Meeting report: 2nd meeting of the European Thoracic Oncology Platform (ETOP). Lung Cancer 2010; 68: 121-124.

(ETOP general) (Journal impact factor 4.486)

 

 

Meeting Abstracts

 

2018

Peters S, De Ruysscher D, Dafni U, Felip E, Guckenberger M, Vansteenkiste JF, Huber RM, Nadal-Alforja E, Irigoyen A, Becker A, Piguet A-C, Kassapian M, Gasca-Ruchti A, Martinez Marti A, Andratschke N, Lambrecht M, Belka C, Roschitzki-Voser H, Stahel RA. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial. Presented at the ASCO Annual Meeting 2018 in Chicago, Illinois. Journal of Clinical Oncology 36, 2018 (suppl; abstr 8510)

(ETOP NICOLAS) (Journal impact factor 26.303)

 

Van Seijen M, Brcic L, Navarro A, Sansano I, Béndek M, Witte B, Brcic I, Kammler R, Stahel RA, Thunnissen E. 21P Influence of delayed and prolonged fixation on the evaluation of immune-histochemical staining on pulmonary resection specimen. Presented at ELCC 2018 in Geneva, Switzerland. Journal of Thoracic Oncology 2018; 13 (4Suppl): S11.

(ETOP Lungscape) (Journal impact factor 10.336)

 

 

2017

Thunnissen E, Dafni U, Bubendorf L, Warth A, Biernat W, Pokharel S, Dziadziuszko R, Dienemann H, Cheney R, Marti N, Kassapian M, Finn S, Kerr KM, Kammler R, Stahel RA, Peters S; Etop Lungscape. Assessment of RANK Prevalence and Clinical Significance in the NSCLC European Thoracic Oncology Platform Lungscape Cohort. Presented at the 18th IASLC WCLC 2017 in Yokohama, Japan. Journal of Thoracic Oncology 2017; 12 (11Suppl 2): S1821-S1822.

(ETOP Lungscape) (Journal impact factor 10.336)

 

Kerr KM, Thunnissen E, Dafni U, Soltermann A, Finn SP, Bubendorf L, Verbeken E, Biernat W, Warth A, Marchetti A, Speel EJM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Polydoropoulou V, Kammler R, Peters S, Stahel RA; Lungscape Consortium. Association of programmed cell death 1 ligand (PD-L1) expression with molecular alterations in non-small cell lung cancer (NSCLC) patients (pts): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort. Presented at the ESMO Congress 2017 in Madrid, Spain. Annals of Oncology (2017) 28 (Suppl 5): mdx390.002.

(ETOP Lungscape) (Journal impact factor 13.926)

 

Kerr KM, Thunnissen E, Dafni U, Soltermann A, Finn SP, Bubendorf L, Verbeken E, Biernat W, Warth A, Marchetti A, Speel EJM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Bille Madsen A, Polydoropoulou V, Kammler R, Peters S, Stahel RA; ETOP Lungscape Consortium. Prevalence and clinical correlation of programmed cell death 1 ligand (PD-L1) expression in patients with resected non-small cell lung cancer (NSCLC): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort. Presented at the ASCO Annual Meeting 2017 in Chicago, IL, USA. Journal of Clinical Oncology 2017; 35 (Suppl 15): 8516-8516.

(ETOP Lungscape) (Journal impact factor 26.303)

 

Smit EF, Peters S, Dziadziuszko R, Dafni U, Wolf J, Wasąg B, Biernat W, Finn S, Kammler R, Tsourti Z, Rabaglio M, Ruepp B, Roschitzki-Voser H, Stahel RA, Felip E. A single-arm phase II trial of afatinib in pretreated patients with advanced NSCLC harboring a HER2 mutation. The ETOP NICHE trial. Presented at the ASCO Annual Meeting 2017 in Chicago, IL, USA. Journal of Clinical Oncology 2017; 35 (Suppl 15): 9070-9070.

(ETOP NICHE) (Journal impact factor 26.303)

 

Peters S, Stahel RA, Kassapian M, Guckenberger M, Felip E, De Langen AJ, Huber RM, Roschitzki-Voser H, Piguet AC, De Ruysscher D. A feasibility trial evaluating the addition of nivolumab to standard first-line chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: The ETOP 6-14 NICOLAS trial. Presented at the European Lung Cancer Conference 2017 in Geneva, Switzerland. Annals of Oncology 2017; 28 (Suppl 2): mdx092.009.

(ETOP NICOLAS) (Journal impact factor 13.926)

 

Finn S, Letovanec I, Zygoura P, Smyth P, Soltermann A, Bubendorf L, Speel EJ, Marchetti A, Nonaka D, Monkhorst K, Hager H, Martorell M, Sejda A, Cheney R, Hernandez-Losa J, Verbeken E, Weder W, Savic S, Di Lorito A, Navarro A, Felip E, Warth A, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dienemann H, Dziadziuszko R, Vansteenkiste J, Geiger T, Sherlock J, Schageman J, Dafni U, Kammler R, Kerr K, Thunnissen E, Peters S, Stahel R; ETOP Lungscape Consortium. Evaluation of NGS and rt-PCR methods for ALK assessment in European NSCLC patients: Results from the ETOP Lungscape project. Presented at the 17th IASLC WCLC 2016 in Vienna, Austria. Journal of Thoracic Oncology. 2017; 12 (Suppl 1): S501–S502.

(ETOP Lungscape) (Journal impact factor 10.336)

 

 

2016

De Ruysscher D, Pujol JL, Popat S, Reck M, Le Pechoux C, Liston A, Speiser D, Coukos G, Kammler R, Dafni U, Tsourti Z, Roschitzki H, Finlayson M, Piguet AC, Ruepp B, Maibach R, Stahel RA, Peters S. STIMULI: A randomised open-label phase II trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after standard of care chemo-radiotherapy conducted by ETOP and IFCT. Presented at the ESMO Congress 2016 in Copenhagen, Denmark. Annals of Oncology 2016; 27 (Suppl 6): vi493–vi496.

(ETOP STIMULI) (Journal impact factor 13.926)

 

Soltermann A, Rulle U, Dafni U, Verbeken E, Thunnissen E, Warth A, Cheney R, Sejda A, Speel E-J, Bille Madsen L, Nonaka D, Navarro A, Sansano I, Marchetti A, Finn S, Kammler R, Schulze K, Bubendorf L, Stahel RA; Lungscape Consortium. Prevalence and clinical associations of PTEN loss in non-small cell lung carcinoma (NSCLC) patients (pts) of the European Thoracic Oncology Platform (ETOP) Lungscape cohort. Presented at the ESMO Congress 2016 in Copenhagen, Denmark. Annals of Oncology 2016; 27 (Suppl 6): vi526–vi544.

(ETOP Lungscape) (Journal impact factor 13.926)

 

Rosell R, Karachaliou N, Giménez-Capitán A, Codony-Servat C, Gautschi O, Felip E, Curioni-Fontecedro A, Peters S, Ponce-Aix S, Früh M, Pless M, Popat S, Cuffe S, Bidoli P, Favaretto A, Kammler R, Dafni U, Tsourti Z, Molina-Vila MA, Stahel RA. The role of BRCA1 and AEG1 mRNA expression in advanced non-small-cell lung cancer (NSCLC) patients (p) with EGFR activating and pretreatment T790M mutations receiving the combination of erlotinib plus bevacizumab (E+B) in the BELIEF trial. Presented at the Annual Meeting of the AACR 2016, New Orleans, LA, USA. American Association for Cancer Research, Cancer Research 2016; 76 (Suppl 14): 269.

(ETOP BELIEF) (Journal impact factor 9.130)

 

 

2015

Stahel RA, Dafni U, Gautschi O, Felip E, Curioni-Fontecedro A, Peters S, Massutí B, Cardenal F, Aix SP, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Carcereny E, Sanchez Ronco M, Molina MA, Rosell R. A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial. Presented at the European Cancer Congress 2015 in Vienna, Austria. European Journal of Cancer. 2015; 51 (Suppl 3): S711.

(ETOP BELIEF) (Journal impact factor 7.191)

 

Kerr KM, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, Gately K, Biernat W, Vliegen L, Hernandez Losa J, Marchetti A, Cheney R, Warth A, Speel EJ, Blackhall F, Molina MA, Shames DS, Peters S, Stahel R. Prevalence and clinical association of gene mutations through Multiplex Mutation Testing in patients with NSCLC: Results from the ETOP Lungscape Project. Presented at the European Cancer Congress 2015 in Vienna, Austria. European Journal of Cancer 2015; 51 (Suppl 3): S595.

(ETOP Lungscape) (Journal impact factor 7.191)

 

Bubendorf L, Dafni U, Finn SP, Warth A, Savic S, Thunnissen E, Sejda A, Verbeken EK, Tischler V, Marchetti A, Sansano I, Speel EJM, Cheney R, Nonaka D, Monkhorst K, Di Lorito A, Consuelo Calabuig M, Reidy M, Hager H, Mathieson W, Martorell M, Baas P, Dienemann H, Smit EF, Blackhall FH Dingemans AMC, Felip E, Adjei A, Meldgaard P, Weder W, Vansteenkiste J, Dziadziuszko R, Tsourti Z, Kerr KM, Schulze K, Das-Gupta A, Peters S, Stahel RA. Prevalence and clinical association of MET gene amplification in patients with NSCLC: Results from the ETOP Lungscape Project. Presented at the 16th WCLC 2015 in Denver, CO, USA. Journal of Thoracic Oncology 2015; 10 (9): S247.

(ETOP Lungscape) (Journal impact factor 10.336)

 

Letovanec I, Peters S, Tsourti Z, Finn SP, Soltermann A, Bubendorf L, Speel EJM, Marchetti A, Nonaka D, Hager H, Martorell M, Monkhorst K, Sejda A, Cheney R, Sansano I, Verbeken EK, Tischler V, Savic S, Di Lorito A, Consuelo Calabuig M, Felip E, Adjei A, Warth A, Baas P, Meldgaard P, Blackhall FH, Dingemans AMC, Dienemann H, Dziadziuszko R, Vansteenkiste J, Kammler R, Dafni U, Kerr KM, Thunnissen E, Stahel RA. Evaluation of RT-PCR methodology for ALK assessment in patients with NSCLC in Europe: Results from the ETOP Lungscape Project. Presented at the 16th WCLC 2015 in Denver, CO, USA. Journal of Thoracic Oncology 2015; 10 (9): S693-S94.

(ETOP Lungscape) (Journal impact factor 10.336)

 

Peters S, Smit EF, Dafni U, Aix SP, Massuti B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Floriani IC, Kassapian M, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Zielinski C, Gregorc V, Stahel RA; EMPHASIS Collaborative Group. Randomized phase III trial of Erlotinib vs. Docetaxel in patients with advanced squamous cell non-small cell lung cancer (SqNSCLC) failing first line platinum based doublet chemotherapy stratified by VeriStrat Good vs VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS trial. Presented at the ASCO Annual Meeting 2015 in Chicago, IL, USA. Journal of Clinical Oncology 2015; 33 (Suppl 15): 8049.

(ETOP 3-12 EMPHASIS) (Journal impact factor 26.303)

 

 

2014

Bubendorf L, Dafni U, Tischler V, Finn SP, Biernat W, Verbeken E, Hager H, Murtra N, Thunnissen E, Nonaka D, Warth A, Speel EJM, Savic S, Martorell M, Tsourti Z, Schulze K, Das Gupta A, Kerr KM, Peters S, and Stahel RA. Prevalence and clinical outcomes for patients with MET protein expression in patients with non-small cell lung cancer in Europe: Results from the European Thoracic Oncology Platform Lungscape Project. Presented at the ESMO Congress 2014 in Madrid, Spain. Annals of Oncology 2014; 25 (Suppl 4): iv418.

(ETOP Lungscape) (Journal impact factor 13.926)

 

 

2013

Kerr KM, Thunnissen E, Blackhall FH, Dafni U, Bubendorf L, Hager H, Soltermann A, O'Byrne KJ, Marchetti A, Dooms C, Sejda A, Sansano I, Nonaka D, Cheney R, De Jong J, Speel EJM, Jantus-Lewintre E, Zhang YJ, Stahel RA, and Peters S. ALK immunohistochemistry and fluorescence in-situ hybridization in lung adenocarcinomas from the ETOP Lungscape tumour cohort. Presented at 15th WCLC 2013 in Sydney, Australia. Journal of Thoracic Oncology 2013; 8 (Suppl 2): S318-319.

(ETOP Lungscape) (Journal impact factor 10.336)

 

Peters S, Weder W, Meldgaard P, O'Byrne KJ, Wrona A, Dooms C, Hernandez-Losa J, Marchetti A, Nicolson M, Tan Q, Smit EF, Dingemans AMC, Savic S, Blackhall FH, Baas P, Jantus-Lewintre E, Kerr KM, Dafni U, Rosell R, Stahel RA, European Thoracic Oncology Platform (ETOP). The European Thoracic Oncology Platform Lungscape project: Clinical outcome data as a basis for molecular correlations in resected non-small cell lung cancer. Presented at the ASCO Annual Meeting 2013 in Chicago, IL, USA. Journal of Clinical Oncology 2013; 31 (Suppl; abstr 7514).

(ETOP Lungscape) (Journal impact factor 26.303)

 

 

2012

Peters S, Dafni O, Bubendorf L, Meldgaard P, O'Byrne KJ, Wrona A, Weder W, Canela M, Malatesta S, Vansteenkiste JF, Dingemans AMC, Nicolson MC, Savic S, Baas P, Peck R, Lu S, Smit EF, Jantus-Lewintre E, Rosell R, and Stahel RA; on behalf of ETOP. The European Thoracic Oncology Platform Lungscape project. A way to bridge non-small cell lung cancer molecular characteristics and clinical data. Presented at the ESMO Congress 2012 in Vienna, Austria. Annals of Oncology 2012; 23 (Suppl 9): ix385.

(ETOP Lungscape) (Journal impact factor 13.926)

 

Blackhall FH, Peters S, Kerr KM, O'Byrne KJ, Hager H, Sejda A, Soltermann A, Dooms C, Felip E, Marchetti A, Speel EJM, Price N, Savic S, De Jong J, Martorell M, Thunnissen E, Bubendorf L, Dafni O, Rosell R, and Stahel RA; on behalf of ETOP. Prevalence and clinical outcomes for patients with ALK gene rearrangement in Europe: Preliminary results from the European Thoracic Oncology Platform Lungscape project. Presented at the ESMO Congress 2012 in Vienna, Austria. Annals of Oncology 2012; 23 (Suppl 9): ix73.

(ETOP Lungscape) (Journal impact factor 13.926)

 

Stahel RA. Lung Cancer: The European Thoracic Oncology Platform. Presented at the ESMO Congress 2012 in Vienna, Austria. Annals of Oncology 2012; 23 (Suppl 9): ix58.

(ETOP general) (Journal impact factor 13.926)

 

Normanno N, Patton S, Blackhall FH, Murray S, Kerr KM, Dietel M, Filipits M, Benlloch S, Stahel RA, and Thunnissen E. Results of the second pilot external quality assurance scheme for somatic EGFR mutation testing in non-small cell lung cancer (NSCLC). Presented at the ESMO Congress 2012 in Vienna, Austria. Annals of Oncology 2012; 23 (Suppl 9): ix86.

(ETOP Lungscape) (Journal impact factor 13.926)

 

Thunnissen E, Kerr KM, Bubendorf L, Nonaka D, Blackhall FH, Kammler R, Speel EJM, De Jong J, Martorell M, and Stahel RA; on behalf of ETOP. External quality assessment for ALK immunohistochemistry testing in lung adenocarcinoma within the European Thoracic Oncology Platform Lungscape project. Presented at the ESMO Congress 2012 in Vienna, Austria. Annals of Oncology. 2012; 23 (Suppl 9): ix80.

(ETOP Lungscape) (Journal impact factor 13.926)

 

Stahel RA, Blackhall FH, Peters S, Bubendorf L, Dafni O, Kerr KM, Taron M, Thunnissen E, Weder W, and Rosell R. The Lungscape project. Presented at ELCC 2012 in Geneva, Switzerland. Journal of Thoracic Oncology 2012; 7 (6): S13-S13.

(ETOP Lungscape) (Journal impact factor 10.336)

 

Peters S, Blackhall FH, Taron M, Rosell R, Hiltbrunner A, Maibach R, King R, and Stahel RA. ETOP Data system: Combining the comprehensive Lungscape database with a clinical trails platform. Presented at TAT 2012 in Amsterdam, the Netherlands. Annals of Oncology 2012; 23 (Suppl 1): i41.

(ETOP Lungscape) (Journal impact factor 13.926)

 

Stahel RA, Peters S, Blackhall FH, Bubendorf L, Dafni U, Kerr KM, Taron M, Thunnissen E, Weder W, Smit E, and Rosell R. ETOP activity in the field of biomarkers and predictors. Presented at BTOG 2012 in Dublin, Ireland. Lung Cancer 2012; 77 (Suppl 1): S16-S17.

(ETOP general) (Journal impact factor 4.486)

 

 

2011

Blackhall FH, Peters S, Kerr KM, Kulig K, Bubendorf L, Thunnissen E, Dziadziuszko R, O’Byrne KJ, Baas P, Weder W, Taron M, Rosell R, and Stahel RA. ALK Gene Rearrangement: Prevalence and clinical outcomes in patients with non-small cell lung cancer (NSCLC) in Europe – A European Thoracic Oncology Group (ETOP) Lungcape Study. Presented at the 14th WCLC 2011 in Amsterdam, the Netherlands. Journal of Thoracic Oncology 2011; 6 (6 Suppl 2): S903-S1688.

(ETOP Lungscape) (Journal impact factor 10.336)

Peters S, Blackhall FH, Boffetta P, Kerr KM, Taron M, Bubendorf L, Ciardiello F, Rosell R, Weder W, King R, and Stahel RA. Building a Comprehensive Database for the Lungscape Project: A Way to Bridge Genomics and Clinical Practice in the European Thoracic Oncology Platform (ETOP). Presented at the 14th WCLC 2011 in Amsterdam, the Netherlands. Journal of Thoracic Oncology 2011; 6 (6Suppl 2): S903-S1688.

(ETOP Lungscape) (Journal impact factor 10.336)

Stahel RA, Blackhall FH, Peters S, Kerr KM, Taron M, Bubendorf L, Weder W, Boffetta P, Ciardiello F, and Rosell R; on behalf of ETOP. Lungscape - a project of the European Thoracic Oncology Platform (ETOP). Presented at TAT 2011 in Paris, France. Annals of Oncology 2011; 22 (Suppl 3): iii26-iii28.

(ETOP Lungscape) (Journal impact factor 13.926)